Mouse Anti-VEGFA Recombinant Antibody (clone mAb G6-31) (CAT#: HPAB-0330CQ)

This product is a recombinant mouse antibody that recognizes VEGFA. G6-31 recognises a VEGF epitope which is conserved between human and mouse VEGF and overlaps with the receptor binding surface.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
FuncS

Figure 1 Assessment of G6–31 activity against lung lesions when administrated intraperitoneally.

Figure 1 Assessment of G6–31 activity against lung lesions when administrated intraperitoneally.

(A) Experimental procedure; Four month-old K-rasLA1 mice received G6–31 or an isotype control, administrated by i.p injection or aerosol, once a week for 4 wk. At the time of death visible lesions were counted on the whole lungs. (B) Quantification of visible nodules per mouse (n = 15 mice per group; 2.5 mg/kg and 10 mg/kg; *P< 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of nodules. (C) Quantification of lung lesions on H&E stained sections from control and G6–31 treated group (n = 15 mice per group; 2.5 mg/kg and 10 mg/kg; P< 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of the number of lesions.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

FuncS

Figure 2 Assessment of aerosolized G6–31 activity against lung lesions.

Figure 2 Assessment of aerosolized G6–31 activity against lung lesions.

(A) Quantification of visible nodules per mouse (n = 15 mice per group; 2.5 mg/kg and 10 mg/kg; *P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of nodules. (B) Quantification of lung lesions on H&E stained sections from control and G6–31 treated group (n =15 mice per group; 2.5 mg/kg and 10 mg/kg; P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of the number of lesions.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

FuncS

Figure 3 Effect of G6–31 at 10 mg/kg administered by i.p. injection or aerosol on K-ras LA1 lung tumors according to each lesion type and effect on microvascular density.

Figure 3 Effect of G6–31 at 10 mg/kg administered by i.p. injection or aerosol on K-ras LA1 lung tumors according to each lesion type and effect on microvascular density.

(A) Quantification of AAH (atypical alveolar hyperplasia), Ad (adenoma) and ADC (adenocarcinoma), on H&E stained lung sections from control and G6–31-treated (10 mg/kg dose) mice (n = 30 mice per group; *P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of the number of each lesion type. (B) Representative image of vWFimmunostaining in the lung of K-ras LA1 mice. Bold arrow shows large vessel while standard arrow shows small vessel. (C) Quantification of the microvascular density, from vWFimmunostaining in control and G6–31-treated (10 mg/kg dose) mice (n = 30 mice per group; *P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

FuncS

Figure 4 Detection of PCNA by western blotting in whole lung protein extracts from control mice (mice 1–4) and G6–31-treated (10 mg/kg) mice (mice 5–9).

Figure 4 Detection of PCNA by western blotting in whole lung protein extracts from control mice (mice 1–4) and G6–31-treated (10 mg/kg) mice (mice 5–9).

Pulmonary delivery is on the right and i.p. delivery is on the left.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

FuncS

Figure 5 CC-3 immunostaining.

Figure 5 CC-3 immunostaining.

Representative images of the control (left) and G6–31 (10 mg/kg dose) delivered either by i.p. (middle) or by pulmonary route (right). Brown cells are positive for CC-3 (arrows show some representative cells). The slices were counterstained with hematoxylin (× 400 magnification).

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

FuncS

Figure 6 Quantification of apoptosis in tumor lesions of the right lung of K-ras LA1 mice (n = 15 mice per group; *P < 0.05 Mann-Whitney test).

Figure 6 Quantification of apoptosis in tumor lesions of the right lung of K-ras LA1 mice (n = 15 mice per group; *P < 0.05 Mann-Whitney test).

Results are expressed as the mean staining scores of CC-3 positive cells relative to the control group ± SEM.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

Block

Figure 7 Blockade of VEGFR2 signaling pathway.

Figure 7 Blockade of VEGFR2 signaling pathway.

Phospho-VEGFR2 Y1175, total VEGFR2, Phospho-PI3K, b-actin, Phospho-AKT, total AKT, Phospho-ERK and total ERK were analyzed by western blotting in whole lung protein extracts from control mice (mice 1–4) and from mice treated with G6–31 at 10 mg/kg (mice 5–9). Pulmonary delivery is on the right and i.p. delivery is on the left.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

ELISA

Figure 8 Pharmacokinetics of G6–31.

Figure 8 Pharmacokinetics of G6–31.

Serum concentration of G6–31 mAb was measured by ELISA in the serum collected at different time points from mice that received a single dose of the mAb (10 mg/kg) either by the pulmonary route (left, n = 13) or intravenously (right, n = 15). Gray area and solid line show the 5th-95th and 50th percentiles of the model-predicted time-concentration profiles, respectively.

Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.

FuncS

Figure 9 Mab G6-31 treated Drd2-/- female mice.

Figure 9 Mab G6-31 treated Drd2-/- female mice.

A) Pituitary weight in vehicle (N=5) and Mab G6-31 treated (N=7) Drd2-/- female mice, * p <0.05 vs vehicle Drd2-/- treated mice. B) Serum prolactin levels in female Drd2-/- vehicle (N=5) or Drd2-/- Mab G6-31 treated mice (N=7). C) Pituitary prolactin concentration (ng/gland) in control Drd2-/-, Mab G6-31 treated Drd2-/- and wild-type (WT) female mice (N=5, 5 and 5, respectively). D) Percent of prolactin positive area by confocal immunohistochemistry in control Drd2-/- and Mab G6-31 treated Drd2-/- and wild-type (WT) female mice (N=6, 7 and 5 respectively), * p<0.05 vs. Drd2-/- vehicle treated mice.

Luque, G. M., Perez-Millán, M. I., Ornstein, A. M., Cristina, C., & Becu-Villalobos, D. (2011). Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. Journal of Pharmacology and Experimental Therapeutics, 337(3), 766-774.

FuncS

Figure 10 Percent of PCNA stained cells (positive PCNA nuclei X 100/ total nuclei) evaluated by immunohistochemistry in control Drd2-/-, Mab G6-31 treated Drd2-/-, and wild-type (WT) female mice (N=6, 6 and 4 respectively), * p <0.05 vs. Drd2-/- vehicle treated mice.

Figure 10 Percent of PCNA stained cells (positive PCNA nuclei X 100/ total nuclei) evaluated by immunohistochemistry in control Drd2-/-, Mab G6-31 treated Drd2-/-, and wild-type (WT) female mice (N=6, 6 and 4 respectively), * p <0.05 vs. Drd2-/- vehicle treated mice.

Luque, G. M., Perez-Millán, M. I., Ornstein, A. M., Cristina, C., & Becu-Villalobos, D. (2011). Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. Journal of Pharmacology and Experimental Therapeutics, 337(3), 766-774.


Specifications

  • Immunogen
  • mVEGF
  • Host Species
  • Mouse
  • Derivation
  • Chimeric (mouse/human)
  • Type
  • Chimeric (mouse/human) IgG
  • Specificity
  • Human VEGFA
  • Species Reactivity
  • Human, Mouse
  • Clone
  • mAb G6-31
  • Applications
  • ELISA, IF, Block, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • This antibody has been tested for use in Enzyme-linked Immunosorbent Assay, Blocking and Functional Assay. Please see the Published Data for further information.

Target

  • Alternative Names
  • Vascular Endothelial Growth Factor A; Vascular Permeability Factor; VEGF; VPF; Vascular Endothelial Growth Factor A121; Vascular Endothelial Growth Factor A165; Vascular Endothelial Growth Factor; VEGF-A; MVCD1;

Related Resources

  • Citations

Shen, Jingjing, et al. "Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment." Science advances 9.4 (2023): eabq3104.

This study focuses on developing an innovative delivery system for macromolecular ophthalmic drugs to treat ocular fundus diseases using eyedrop formulations. Traditional treatments like intravitreal injections present risks such as infections and retinal detachment. This research introduces a penetrating carrier based on fluorocarbon-modified chitosan (FCS), which can self-assemble with proteins to form nanocomplexes. These nanocomplexes effectively traverse ocular barriers to reach the posterior eye segments, demonstrating superior therapeutic responses in mouse models of choroidal melanoma and choroidal neovascularization compared to conventional methods. The FCS/anti-PDL1 and FCS/anti-VEGFA eyedrops induced stronger antitumor immune responses and inhibited vascular proliferation, respectively, showcasing the potential for at-home treatment of various eye diseases.
In this study, Creative Biolabs provided crucial therapeutic antibodies that were integral to the research. Specifically, they supplied anti-VEGFA (Cat#: HPAB-0330CQ), which was used in the formulation of FCS/anti-VEGFA nanocomplexes for treating choroidal neovascularization. This antibody played a pivotal role in achieving comparable therapeutic effects to intravitreal injections, thus validating the efficacy of the new delivery system. The contributions of Creative Biolabs significantly advanced the study, highlighting the potential for noninvasive, effective treatment options for ocular diseases.

More Infomation

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone mAb G6-31"

See other products for "VEGFA"

Select a product category from the dropdown menu below to view related products.
Please select product type
Humanized Antibody Products Immunotoxin Products IgG Antibody Products Fab Antibody Products Mouse Antibody Products Human Antibody Products Chicken IgY Antibody Products Neutralizing Antibody Products Blocking Antibody Products Rabbit Monoclonal Antibody Products IgM Antibody Products ADCC Enhanced Antibody Products ScFv Antibody Products Single Domain Antibody Products Antibody Magnetic Beads Non-Human Primate (NHP) Antibody Products
CAT Product Name Application Type
TAB-H73 Anti-Human VEGFA Recombinant Antibody (Vanucizumab) WB, FC, IP, ELISA, Neut, FuncS, IF VH - C-kappa - CH2 - CH3 _ V-lambda - CH1 _ H-GAMMA-1 _ L-kappa
TAB-011 Anti-Human VEGF Recombinant Antibody (Bevacizumab) FC, IP, ELISA, Neut, FuncS, IF, ICC IgG1 - kappa
TAB-012-F(E) Anti-Human VEGF Recombinant Antibody Fab Fragment (Ranibizumab) IP, IF, FuncS, FC, Neut, ELISA, IHC Fab - G1 - kappa
TAB-307CQ-S(P) Human Anti-VEGFA Recombinant Antibody; scFv Fragment (TAB-307CQ-S(P)) ELISA, Neut Human scFv
TAB-009ML Anti-Human VEGFA Recombinant Antibody scFv Fragment (Brolucizumab) ELISA, IHC, FC, IP, IF, Inhib scFv, κ

Customer Reviews and Q&As

Customer Review Q&As

Submit a review or a question

  • Excellent for VEGFA Research
    The Anti-VEGFA Recombinant Antibody has been excellent for our VEGFA studies. Its specificity and sensitivity are outstanding, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.
  • Effective and Dependable
    We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for VEGFA is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.
  • Consistent High-Quality Results
    This antibody has proven to be consistent and dependable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for VEGFA have been particularly beneficial.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# HPAB-0330CQ, RRID: AB_3111386)

Copy citation

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare